Pioneering insulin dose mobile app gets US approval

The first mobile app that determines insulin doses for people with type 2 diabetes has been officially approved in the US.
The app, designed to work alongside the d-Nav Insulin Guidance Service, has been given the seal of approval by the US Food and Drug Administration (FDA).
The organisation gave the technology 510(k) clearance, which means it deems the app safe and effective enough to be publicly marketed.
The d-Nav platform is the first insulin-management phone app able to calculate individualised doses for all types of insulin regimens, and also the first insulin-titration app that can connect to any blood glucose meter that shares data with the cloud.
Available for both iOS and Android, the app could potentially make life a lot of easier for people with type 2 diabetes, according to Hygieia, the company that developed the technology.
Hygieia’s CEO Eran Basha, said: “This FDA clearance is an important milestone in our mission to improve and simplify insulin management by making the d-Nav Service as convenient, simple and accessible as possible for patients and physicians who could benefit from it.”
The d-Nav service has been in use in Northern Ireland for more than six years, and Hygieia says it is exploring opportunities to make the app available to other countries and markets in the future.
On the website, Hygieia describes its product as being “similar to a GPS”.
It added: “d-Nav functions as a guide for insulin users. It knows your destination and the roads that lead there. If it senses that you’ve taken a wrong turn, d-Nav immediately alerts you, providing directions so that you can resume your journey on a better path.”
Uniquely, the d-Nav service also includes nursing support and each user can communicate with their healthcare in person or by phone.
Editor’s note: People with type 2 diabetes may be able to come off insulin medication through eating a healthy, real-food diet. For more information visit our multi-award-winning Low Carb Program.